InMode (NASDAQ:INMD) Updates FY25 Earnings Guidance

InMode (NASDAQ:INMD) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided EPS guidance of $1.95-$1.99 for the period, compared to the consensus EPS estimate of $1.98. The company issued revenue guidance of $395-$405 million, compared to the consensus revenue estimate of $413.47 million.

Wall Street Analysts Forecast Growth

INMD has been the topic of a number of recent research reports. Barclays reduced their target price on InMode from $27.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 9th. BTIG Research started coverage on InMode in a research report on Thursday, October 17th. They set a “buy” rating and a $25.00 price objective for the company. Finally, Needham & Company LLC restated a “hold” rating on shares of InMode in a report on Tuesday. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $22.40.

InMode Price Performance

NASDAQ:INMD traded up $0.67 during mid-day trading on Tuesday, reaching $17.34. The company’s stock had a trading volume of 1,150,249 shares, compared to its average volume of 847,100. InMode has a twelve month low of $14.87 and a twelve month high of $26.80. The company’s fifty day simple moving average is $17.48 and its two-hundred day simple moving average is $17.20. The stock has a market cap of $1.46 billion, a P/E ratio of 9.36 and a beta of 2.13.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.